Astrana Health, Inc. $ASTH Shares Sold by Royce & Associates LP

Royce & Associates LP decreased its position in Astrana Health, Inc. (NASDAQ:ASTH) by 15.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 259,353 shares of the company’s stock after selling 48,135 shares during the quarter. Royce & Associates LP’s holdings in Astrana Health were worth $7,353,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Amalgamated Bank raised its holdings in shares of Astrana Health by 3.4% in the 3rd quarter. Amalgamated Bank now owns 12,325 shares of the company’s stock valued at $349,000 after purchasing an additional 409 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in Astrana Health by 1.5% in the third quarter. Thrivent Financial for Lutherans now owns 30,977 shares of the company’s stock valued at $878,000 after buying an additional 455 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Astrana Health by 0.3% during the 3rd quarter. Principal Financial Group Inc. now owns 222,985 shares of the company’s stock worth $6,322,000 after buying an additional 611 shares during the last quarter. Savant Capital LLC boosted its position in shares of Astrana Health by 2.2% during the 3rd quarter. Savant Capital LLC now owns 30,713 shares of the company’s stock worth $871,000 after acquiring an additional 649 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Astrana Health by 7.1% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,657 shares of the company’s stock valued at $265,000 after acquiring an additional 710 shares during the last quarter. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Trading Up 4.4%

ASTH opened at $25.59 on Thursday. Astrana Health, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $34.80. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.40 and a quick ratio of 1.40. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 55.63, a price-to-earnings-growth ratio of 0.68 and a beta of 0.91. The firm has a 50 day simple moving average of $23.57 and a 200 day simple moving average of $26.24.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Monday, March 2nd. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.39. Astrana Health had a net margin of 0.71% and a return on equity of 5.59%. The company had revenue of $950.53 million for the quarter, compared to analysts’ expectations of $930.46 million. During the same period last year, the firm posted ($0.15) earnings per share. The business’s quarterly revenue was up 42.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Analysts Set New Price Targets

ASTH has been the subject of several recent analyst reports. Barclays decreased their target price on Astrana Health from $36.00 to $26.00 and set an “equal weight” rating for the company in a research note on Monday, November 24th. Needham & Company LLC assumed coverage on shares of Astrana Health in a research report on Friday, December 12th. They set a “buy” rating and a $28.00 price objective for the company. TD Cowen dropped their target price on shares of Astrana Health from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Astrana Health in a research note on Monday, December 29th. Finally, BTIG Research decreased their price objective on shares of Astrana Health from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $35.33.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.